Free Trial
NASDAQ:ABVX

Abivax Q1 2026 Earnings Results & Report

Abivax logo
$83.61 -3.97 (-4.53%)
Closing price 04:00 PM Eastern
Extended Trading
$83.52 -0.09 (-0.11%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abivax beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 22, 2026. The company reported EPS of -$0.71 versus the -$0.9359 consensus estimate, while revenue of $1.56 million topped the $401 thousand estimate by $1.15 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
11:40 AM ET

Abivax EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.9359
Beat/Miss
Beat by +$0.2259
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Abivax Revenue Results

Actual Revenue
$1.56 million
Expected Revenue
$401 thousand
Beat/Miss
Beat by +$1.15 million
YoY Revenue Growth
N/A

Upcoming Earnings

Abivax's Q3 2026 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Monday, December 14, 2026 at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Abivax Q1 2026 Earnings FAQ

Abivax (NASDAQ:ABVX) reported earnings of -$0.71 per share for Q1 2026, beating the consensus estimate of -$0.9359. The report was announced on Friday, May 22, 2026.

Abivax reported revenue of $1.56 million for Q1 2026, against a consensus estimate of $401 thousand.

Abivax's next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Abivax on the company's earnings history page.

Abivax Earnings Headlines

Abivax to Participate in Upcoming Fall Investor Conferences
The $40 trillion number nobody won on Tuesday will touch
Democrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion a year in interest on it didn't change. Central banks bought 863 tonnes of gold in 2025 and another 289 tonnes in the second quarter of this year. Gold broke $5,000 and had its best year since 1979 in 2025. Wall Street's biggest bank forecasts gold above $6,000 by early 2027.tc pixel
Abivax SA ADR ABVX
See More Abivax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email.

About Abivax

Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response.

The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation.

Founded in 2013, Abivax conducts clinical development internationally. Marc de Garidel has served as the company’s chief executive officer.

View Abivax Profile